ReviewCancers2021

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer.

Ameya D Puranik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.